Lara Meisner - 15 Jun 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Legal Officer
Signature
/s/ Kristian Humer, Attorney-in-Fact for Lara Meisner
Issuer symbol
VRDN
Transactions as of
15 Jun 2023
Transactions value $
-$11,466
Form type
4
Filing time
20 Jun 2023, 17:23:01
Previous filing
06 Jun 2023
Next filing
12 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $52.3K +2.27K +7.57% $23.03 32.2K 15 Jun 2023 Direct
transaction VRDN Common Stock Sale -$63.6K -2.27K -7.04% $28.02 30K 15 Jun 2023 Direct F1
transaction VRDN Common Stock Options Exercise $622 +27 +0.09% $23.03 30K 16 Jun 2023 Direct
transaction VRDN Common Stock Sale -$765 -27 -0.09% $28.35 30K 16 Jun 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -2.27K -5.71% $0.00 37.5K 15 Jun 2023 Common Stock 2.27K $23.03 Direct F3
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -28 -0.07% $0.00 37.5K 16 Jun 2023 Common Stock 28 $23.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed pursuant to the Plan.
F3 The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.